GlassScriptPhysician profile
Sam R Shimamoto
NPI 1073587382
$35,995.55
in general payments reported to CMS, 2019-2025
40 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $3,002 · 2021: $7,861 · 2022: $2,190 · 2023: $1,776 · 2024: $6,139 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,618 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,260 · Education: $235 · Consulting Fee: $210 · Travel and Lodging: $28.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,617.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,260.00 |
| Education | $235.14 |
| Consulting Fee | $210.47 |
| Travel and Lodging | $28.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $26,413.57 | 2019-2025 | Xolair |
| Regeneron Pharmaceuticals, INC. | $3,103.16 | 2020-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $663.95 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $650.43 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $590.85 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Glaxosmithkline, LLC. | $483.95 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $462.69 | 2022-2025 | Tezspire |
| Genzyme Corporation | $450.76 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $315.22 | 2019-2025 | |
| Pharming Healthcare, INC. | $284.24 | 2022-2025 | Ruconest |
| Genentech, INC. | $253.35 | 2024-2025 | Xolair |
| Csl Behring | $233.19 | 2020-2025 | Hizentra, Haegarda, Privigen |
| Grifols USA, LLC | $224.17 | 2022-2025 | Xembify |
| Adma Biomanufacturing LLC | $210.47 | 2023-2025 | |
| Pfizer INC. | $181.98 | 2019-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $160.89 | 2022-2025 | Adbry, Anzupgo |
| Sanofi-Aventis U.S. LLC | $160.36 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $159.45 | 2023-2025 | Orladeyo |
| Kaleo, INC. | $140.85 | 2022-2024 | Auvi-Q |
| Incyte Corporation | $131.15 | 2023-2025 | Opzelura |
| Abbvie INC. | $88.58 | 2022-2025 | Rinvoq |
| Optinose US, INC. | $70.75 | 2023-2025 | |
| Blueprint Medicines Corporation | $63.95 | 2024-2025 | Ayvakit |
| Organon LLC | $61.01 | 2025 | Vtama, Nexplanon |
| Greer Laboratories, INC. | $58.19 | 2024 | Palforzia |
| Gc Biopharma USA, INC. | $56.29 | 2025 | Alyglo |
| Lilly USA, LLC | $47.56 | 2025 | Ebglyss |
| Kedrion Biopharma, INC. | $40.52 | 2023-2024 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Hikma Pharmaceuticals USA | $38.86 | 2025 | Ryaltris |
| Mylan Specialty L.P. | $36.00 | 2024 | Yupelri |
| Shire North American Group INC | $30.32 | 2019 | |
| Covis Pharma Gmbh | $30.12 | 2022 | |
| Aimmune Therapeutics, INC. | $22.78 | 2023 | |
| Bio Products Laboratory USA, INC. | $22.65 | 2022-2023 | Gammaplex, Coagadex |
| Horizon Therapeutics Plc | $15.97 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.73 | 2022 | |
| Merck Sharp & Dohme LLC | $13.21 | 2023 | |
| Cycle Pharmaceuticals INC | $8.38 | 2024 | Sajazir |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Shimamoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.